| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
29,990,000 |
| Market
Cap: |
2.85(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.062 - $1.22 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Atreca is a clinical-stage biopharmaceutical company utilizing its platform to discover and develop antibody-based immunotherapeutics to treat a range of solid tumor types. Co.'s primary product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. Co. owns worldwide rights to ATRC-101.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
1 |
1 |
1 |
1 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
1 |
1 |
1 |
| Total Shares Sold |
20,788 |
20,788 |
353,058 |
410,690 |
| Total Sell Value |
$1,455 |
$1,455 |
$144,635 |
$250,581 |
| Total People Sold |
1 |
1 |
6 |
6 |
| Total Sell Transactions |
1 |
1 |
9 |
14 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Robinson William Hewitt |
Director |
– • – |
2020-11-16 |
4 |
AS |
$15.00 |
$75,000 |
D/D |
(5,000) |
388,948 |
|
-7% |
|
| Serafini Tito |
Chief Strategy Officer |
• • – |
2020-11-12 |
4 |
GA |
$0.00 |
$0 |
I/I |
3,655 |
3,655 |
|
- |
|
| Serafini Tito |
Chief Strategy Officer |
• • – |
2020-11-12 |
4 |
GD |
$0.00 |
$0 |
D/D |
3,655 |
0 |
|
- |
|
| Serafini Tito |
Chief Strategy Officer |
• • – |
2020-11-11 |
4 |
AS |
$15.10 |
$17,407 |
I/I |
(1,153) |
399,067 |
|
-7% |
|
| Greenberg Norman Michael |
Chief Scientific Officer |
• – – |
2020-11-10 |
4 |
AS |
$15.10 |
$67,963 |
D/D |
(4,500) |
0 |
|
-4% |
|
| Greenberg Norman Michael |
Chief Scientific Officer |
• – – |
2020-11-10 |
4 |
OE |
$4.56 |
$20,520 |
D/D |
4,500 |
4,500 |
|
- |
|
| Greenberg Norman Michael |
Chief Scientific Officer |
• – – |
2020-10-19 |
4 |
AS |
$15.12 |
$7,562 |
D/D |
(500) |
0 |
|
26% |
|
| Greenberg Norman Michael |
Chief Scientific Officer |
• – – |
2020-10-19 |
4 |
OE |
$4.56 |
$2,280 |
D/D |
500 |
500 |
|
- |
|
| Robinson William Hewitt |
Director |
– • – |
2020-10-13 |
4 |
AS |
$15.71 |
$78,531 |
D/D |
(5,000) |
393,948 |
|
10% |
|
| Serafini Tito |
Chief Strategy Officer |
• • – |
2020-10-12 |
4 |
AS |
$15.00 |
$150,000 |
I/I |
(10,000) |
400,220 |
|
13% |
|
| Serafini Tito |
Chief Strategy Officer |
• • – |
2020-10-06 |
4 |
AS |
$15.05 |
$18,334 |
I/I |
(1,218) |
410,220 |
|
27% |
|
| Robinson William Hewitt |
Director |
– • – |
2020-09-18 |
4 |
AS |
$15.04 |
$75,188 |
D/D |
(5,000) |
398,948 |
|
-7% |
|
| Serafini Tito |
Chief Strategy Officer |
• • – |
2020-09-18 |
4 |
AS |
$15.11 |
$132,664 |
I/I |
(8,782) |
411,438 |
|
-7% |
|
| Robinson William Hewitt |
Director |
– • – |
2020-08-14 |
4 |
AS |
$15.00 |
$75,000 |
D/D |
(5,000) |
403,948 |
|
1% |
|
| Serafini Tito |
Chief Strategy Officer |
• • – |
2020-08-14 |
4 |
AS |
$15.00 |
$150,000 |
I/I |
(10,000) |
420,220 |
|
1% |
|
| Robinson William Hewitt |
Director |
– • – |
2020-07-13 |
4 |
AS |
$19.43 |
$101,139 |
D/D |
(5,000) |
408,948 |
|
-23% |
|
| Serafini Tito |
Chief Strategy Officer |
• • – |
2020-07-13 |
4 |
AS |
$19.41 |
$202,018 |
I/I |
(10,000) |
430,220 |
|
-23% |
|
| Greenberg Norman Michael |
Chief Scientific Officer |
• – – |
2020-07-01 |
4 |
AS |
$21.69 |
$224,224 |
D/D |
(10,272) |
0 |
|
-32% |
|
| Greenberg Norman Michael |
Chief Scientific Officer |
• – – |
2020-07-01 |
4 |
OE |
$4.56 |
$46,840 |
D/D |
10,272 |
10,272 |
|
- |
|
| Robinson William Hewitt |
Director |
– • – |
2020-06-25 |
4 |
AS |
$25.02 |
$15,010 |
D/D |
(600) |
413,948 |
|
-37% |
|
| Serafini Tito |
Chief Strategy Officer |
• • – |
2020-06-25 |
4 |
AS |
$25.01 |
$15,008 |
I/I |
(600) |
440,220 |
|
-37% |
|
| Serafini Tito |
Chief Strategy Officer |
• • – |
2020-06-22 |
4 |
AS |
$20.05 |
$9,945 |
I/I |
(496) |
440,820 |
|
-37% |
|
| Robinson William Hewitt |
Director |
– • – |
2020-06-22 |
4 |
AS |
$20.05 |
$1,363 |
D/D |
(68) |
414,548 |
|
-37% |
|
| Serafini Tito |
Chief Strategy Officer |
• • – |
2020-06-19 |
4 |
AS |
$20.03 |
$92,203 |
I/I |
(4,604) |
441,316 |
|
-33% |
|
| Robinson William Hewitt |
Director |
– • – |
2020-06-19 |
4 |
AS |
$20.03 |
$205,169 |
D/D |
(10,245) |
414,616 |
|
-33% |
|
132 Records found
|
|
Page 3 of 6 |
|
|
